Sign Out
Hypersensitivity to lorlatinib or to any of the excipients listed in Description.
Concomitant use of strong CYP3A inducers with lorlatinib is contraindicated due to the potential for serious hepatotoxicity (aspartate aminotransferase [AST] and alanine aminotransferase [ALT] elevations) (see Precautions and Interactions).
